Bascom Palmer Eye Institute Added as Site for Stem Cell Clinical Trial for Dry AMD

• Share
• E-mail
• Print

Advanced Cell Technology Inc., announced that the Bascom Palmer Eye Institute in Miami has received institutional review board approval as a site for the company’s phase 1/2 clinical trial for dry AMD using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.

The phase 1/2 trial is a prospective, open-label study designed to determine the safety and tolerability of the hESC-derived RPE cells following subretinal transplantation into patients with dry AMD. The trial will enroll 12 patients, with cohorts of 3 patients each in an ascending dosage format.

Advanced Cell Technology will work with the team of Philip Rosenfeld, MD, a retina specialist and professor of ophthalmology at the University of Miami’s Miller School of Medicine. For more information about patient eligibility for the study, visit www.clinicaltrials.gov, identifier: NCT01344993.

Click here for more industry news and clinical trial updates.

Comment on this Article:

You must be logged in to leave a comment.

TOP 5 ARTICLES FROM 2012

• Treatment of Retinal Vein Occlusion

  Individualized therapy is crucial to good patient outcomes.

  By Gaurav K. Shah, MD

• Intravitreal Aflibercept for AMD: 2-year Results

  The VIEW 1 and 2 studies showed high degrees of safety and efficacy at 2 years.

  By Jeffery S. Heier, MD

• Treatment of Vitreomacular Adhesion: Present Status, Future Prospects

  The technology is already in use for diagnosis and management of some conditions.

  By J. Sebag, MD, FACS, FRCOphth, FARVO

• Ocular Drug Delivery Systems for the Posterior Segment: A Review

  By Noriyuki Kuno, PhD; and Shinobu Fujii

• A New Focus on the Vitreous and Its Role in Retinal Function

  By Pravin U. Dugel, MD